Correlation Between Interdialytic Weight Gain and Cardiovascular Diseases in Children With End-Stage Kidney Disease Undergoing Hemodialysis

NCT ID: NCT05549050

Last Updated: 2022-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-08

Study Completion Date

2023-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to discuss the correlation between interdialytic weight gain and cardiovascular diseases in children with end-stage kidney disease undergoing chronic hemodialysis. The cardiovascular parameters used include left ventricular hypertrophy, systolic and diastolic function, carotid intima-media thickness, myocardial circumferential strain, and strain rate.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End Stage Renal Disease on Dialysis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

interdialytic weight gain cardiovascular chronic kidney disease hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interdialytic weight gain

interdialytic weight gain during hemodialysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* End-stage kidney disease (chronic kidney disease stage 5)
* Undergo hemodialysis at least twice a week

Exclusion Criteria

* History of congenital heart disease
* Critically ill patients with unstable hemodynamic status
Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indonesia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Henny Adriani Puspitasari

Consultant of Pediatric Nephrology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Henny A Puspitasari, dr. Sp.A(K)

Role: PRINCIPAL_INVESTIGATOR

Department of Child Health, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cipto Mangunkusumo Hospital

Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Henny A Puspitasari, dr. Sp.A(K)

Role: CONTACT

Phone: +6281218603930

Email: [email protected]

Callen Zulkifli, dr.

Role: CONTACT

Phone: +6285966795947

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Henny A Puspitasari, dr. Sp.A(K)

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-10-1072

Identifier Type: -

Identifier Source: org_study_id